Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Withdrawn before enrolling · Not applicable

Conditions studied: Ovarian Cancer

In brief

The investigators propose to totally abolish the emesis (vomiting) associated with the regimen of oxaliplatin + topotecan by adding a daily administration of aprepitant (Emend) for 17 days to the HT3 blocker routinely given on days 1 and 15.

Key facts

Study ID

NCT01017809

Run by

NYU Langone Health

People needed

0

Starts

2010-12-01

Expected to finish

2013-12-01

Last updated by the study team

2015-03-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All patients fulfilling the requirement for entering the study NYU 03-67 will be eligible to enter the supplementary protocol with Emend. Please see NCT0031361 for eligibility.

You may not qualify if…

• Patients not enrolled on NYU 03-67(NCT0031361).

Where it is running

• NYU Clinical Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.